Posted by Michael Wonder on 25 Apr 2020
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems
24 April 2020 - Close supervision is strongly recommended.
The FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines.
The FDA is also aware of increased use of these medicines through outpatient prescriptions.
